Insulin and leptin levels in patients with schizophrenia or related psychoses - A comparison between different antipsychotic agents

Psychopharmacology

Volumn 154, Issue 2, 2001, Pages 205-212

  Melkersson, K I ^a   Hulting, A L ^b  

^a ST GÖRAN S HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antipsychotic agent; Insulin; Leptin; Psychotic disorder; Weight gain

Indexed keywords

CLOZAPINE; GLUCOSE; HYDROCORTISONE; INSULIN; LEPTIN; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; THYROTROPIN; ZUCLOPENTHIXOL;

ARTICLE; BODY MASS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG STRUCTURE; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; WEIGHT GAIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY MASS INDEX; CLOZAPINE; FEMALE; HUMANS; INSULIN; LEPTIN; MALE; MIDDLE AGED; PIRENZEPINE; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; WEIGHT GAIN;

EID: 0035111503     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130000639     Document Type: Article

References (48)

1. Regulation of circulating leptin in humans
2. Diabetic ketoacidosis and clozapine
3. Antipsychotic-induced weight gain: A comprehensive research synthesis
4. 2c receptor antagonist
5. Weight gain associated with psychotropic drugs
6. Serum leptin levels increase rapidly after initiation of clozapine therapy
7. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection
8. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans
9. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: A prospective study
10. Clozapine-associated elevation in serum triglycerides
11. Serum triglyceride levels in patients treated with clozapine
12. Effect of long-term olanzapine treatment on weight change in schizophrenia
13. Non-neurological side effects of anti-psychotic agents
14. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
15. Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high insulin responders
16. Leptin concentrations and insulin sensitivity in normoglycemic men
17. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: Effects of dietary fat content and sustained weight loss
18. Gender differences in serum leptin levels in humans
19. Acute and chronic effect of insulin on leptin production in humans. Studies in vivo and in vitro
20. Ketoaci-dosis as a side-effect of clozapine: A case report
21. Body weight and leptin plasma levels during treatment with antipsychotic drugs
22. Classification of diabetes mellitus
23. A high-performance liquid chromatographic method for the assay of perphenazine and its de-alkylated metabolite in serum after therapeutic doses
24. Receptors for neuroleptic drugs
25. Radioimmunoassay of leptin in human plasma
26. Leptin levels in human and rodent: Measurement of plasma leptin and of obRNA in obese and weight-reduced subjects
27. The role of leptin in human obesity and disease: A review of current evidence
28. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition
29. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses
30. Congenital leptin deficiency is associated with severe early-onset obesity in humans
31. Insulin resistance
32. Olanzapine increases weight and serum triglyceride levels
33. Clozapine and associated diabetes mellitus
34. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men
35. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: Implications for the development of adipogenic diabetes mellitus
36. Olanzapine-induced elevation of plasma triglyceride levels
37. Neuroleptic malignant syndrome and hyperosmolar, non-ketotic hyperglycaemic coma
38. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine
39. Weight gain associated with neuroleptic medication: A review
40. Direct stimulation of basal insulin secretion by physiological concentrations of leptin in pancreatic β cells
41. 2c serotonin receptors
42. Clozapine and weight gain
43. Novel antipsychotics and new onset diabetes
44. Food intake and energy balance
45. The effect of clozapine on glucose metabolism
46. Positional cloning of the mouse obese gene and its human homologue